Medivation (MDVN) Misses Q1 EPS by 12c, Sales Miss; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Medivation (MDVN) Misses Q1 EPS by 12c, Sales Miss; Reaffirms
May 9, 2016 3:57 PM EDT
Needham & Company analyst Chad Messer weighed in on Hold-rated Medivation (NASDAQ: MDVN), saying another Xtandi miss is being overlooked by the takeover battle. The analyst sees little upside from current levels.
Messer commented, "Medivation rejected Sanofi's recent $52.50/share ($9.3 billion) takeover bid. However,... More
May 6, 2016 7:52 AM EDT
Jefferies analyst Biren Amin bumped his price target on Medivation (NASDAQ: MDVN) to $56.00 (from $52.00) but maintained a Hold rating.
Amin commented, "MDVN reported $307.6M in U.S. Xtandi sales despite seasonal headwinds and reiterated sales guidance of $1.425-1.525B in 2016 and issued long term... More
May 6, 2016 7:39 AM EDT
Citi upgraded Medivation (NASDAQ: MDVN) from Neutral to Buy.
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $59.22 yesterday.
...
More
May 6, 2016 6:54 AM EDT
RBC Capital analyst Simos Simeonidis lifted his price target on Medivation (NASDAQ: MDVN) to $70.00 (from $40.00) while maintaining a Sector Perform rating on the stock.
Simeonidis commented, "MDVN reported $548M in WW Xtandi sales, flat Q/Q, but reiterated 2016 guidance on... More
